HBIO PE Ratio & Valuation, Is HBIO Overvalued

Historical Valuation

Harvard Bioscience Inc (HBIO) is now in the Fair zone, suggesting that its current forward PE ratio of 7.67 is considered Fairly compared with the five-year average of 23.82. The fair price of Harvard Bioscience Inc (HBIO) is between 0.27 to 2.42 according to relative valuation method.

Relative Value

Fair Zone

0.27-2.42

Current Price：0.53

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Harvard Bioscience Inc (HBIO) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Harvard Bioscience Inc (HBIO) has a current Price-to-Book (P/B) ratio of 2.07. Compared to its 3-year average P/B ratio of 1.98, the current P/B ratio is approximately 4.49% higher. Relative to its 5-year average P/B ratio of 2.31, the current P/B ratio is about -10.49% higher. Harvard Bioscience Inc (HBIO) has a Forward Free Cash Flow (FCF) yield of approximately 25.60%. Compared to its 3-year average FCF yield of 7.67%, the current FCF yield is approximately 233.83% lower. Relative to its 5-year average FCF yield of 4.31%, the current FCF yield is about 494.17% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for HBIO competitors is 1.82, providing a benchmark for relative valuation. Harvard Bioscience Inc Corp (HBIO.O) exhibits a P/S ratio of 0.32, which is -82.22% above the industry average. Given its robust revenue growth of -6.27%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of HBIO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of HBIO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is HBIO currently overvalued or undervalued?

What is Harvard Bioscience Inc (HBIO) fair value?

HBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Harvard Bioscience Inc (HBIO) is between 0.27 to 2.42 according to relative valuation method.

How does HBIO's valuation metrics compare to the industry average?

The average P/S ratio for HBIO's competitors is 1.82, providing a benchmark for relative valuation. Harvard Bioscience Inc Corp (HBIO) exhibits a P/S ratio of 0.32, which is -82.22% above the industry average. Given its robust revenue growth of -6.27%, this premium appears unsustainable.

What is the current P/B ratio for Harvard Bioscience Inc (HBIO) as of Mar 11 2026?

As of Mar 11 2026, Harvard Bioscience Inc (HBIO) has a P/B ratio of 2.07. This indicates that the market values HBIO at 2.07 times its book value.

What is the current FCF Yield for Harvard Bioscience Inc (HBIO) as of Mar 11 2026?

As of Mar 11 2026, Harvard Bioscience Inc (HBIO) has a FCF Yield of 25.60%. This means that for every dollar of Harvard Bioscience Inc's market capitalization, the company generates 25.60 cents in free cash flow.

What is the current Forward P/E ratio for Harvard Bioscience Inc (HBIO) as of Mar 11 2026?

As of Mar 11 2026, Harvard Bioscience Inc (HBIO) has a Forward P/E ratio of 7.67. This means the market is willing to pay $7.67 for every dollar of Harvard Bioscience Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Harvard Bioscience Inc (HBIO) as of Mar 11 2026?

As of Mar 11 2026, Harvard Bioscience Inc (HBIO) has a Forward P/S ratio of 0.32. This means the market is valuing HBIO at $0.32 for every dollar of expected revenue over the next 12 months.

HBIO Valuation